AstraZeneca PLC has created a scientific review board to assess requests from external researchers to access patient-level data.
The board of independent clinicians and academics has been developed as a part of the company’s commitment to groups including the European Federation of Pharmaceutical Industries and Associations, Pharmaceutical Research and Manufacturers of America Responsible Data Sharing Principles and European Medicines Agency Clinical Trial Policy and Regulation.
Peter Kowey, system chief of the Division of Cardiovascular Diseases for the Lankenau Heart Institute, is the chairman of the board. Other members include Stephen Rennard of the University of Nebraska Medical Center, Simon Day from Clinical Trials Consulting and Training and Alexander Walker from World Health Information Science Consultants.
The board will meet on a regular basis to assess requests for data from AstraZeneca’s clinical trials. Board members will be responsible for examining the scientific validity of requests, as well as how they could improve patient care.